Cannabidiol/tetrahydrocannabinol - Axim Biotech

Drug Profile

Cannabidiol/tetrahydrocannabinol - Axim Biotech

Alternative Names: CBD/THC gum; MedChew 1401; MedChew 1502; MedChew 1503; MedChew 1504; MedChew RX™; Tetrahydrocannabinol/cannabidiol - Axim Biotech

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Axim Biotech
  • Class Analgesics; Antiemetics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dementia; Pain; Parkinson's disease; Restless legs syndrome

Most Recent Events

  • 16 Nov 2016 Axim Biotech receives patent allowance for cannabinoid-containing controlled-release chewing gum products in USA
  • 09 Nov 2016 Axim Biotech announces intention to submit NDA for Parkinson's disease, Dementia, Restless leg syndrome in 2021, 2022, 2020 (Axim Biotech pipeline, November 2016)
  • 09 Nov 2016 Axim Biotech announces intention to submit NDA/MAA for Pain in 2018/2019 (Axim Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top